FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W17537284> ?p ?o ?g. }

• W17537284 endingPage "28" @default.
• W17537284 startingPage "117" @default.
• W17537284 abstract "The nucleotide sequences of genes contain information which can potentially be used to understand gene function and thus the biological properties of living organisms. This information can also be used to develop innovative new strategies for chemotherapy employing sequence-specific non-ionic oligonucleoside methylphosphonates. These oligonucleotide analogs, termed Matagen (an acronym for masking tape for gene expression), have the following properties: (1) the negatively charged phosphodiester linkage normally found in nucleic acids is replaced with a non-charged methylphosphonate group which confers increased lipophilicity to the oligomer; (2) the oligomers form stable hydrogen-bonded complexes with complementary nucleic acid sequences and retain the fidelity of Watson-Crick base pairing; (3) the lipophilic oligomers cross the cell membrane and also enter various organs of the body; and (4) the methylphosphonate backbone is inherently resistant to nuclease hydrolysis and thus oligomers are taken up intact from cell culture media and remain stable within the cellular environment. Two general strategies are used to block gene expression by Matagens at the mRNA level in mammalian cells. In the first approach, Matagens complementary to specific sites such as the initiation codon region are used to block translation of mRNA. Thus Matagens specifically inhibit translation of rabbit globin mRNA in cell-free systems and rabbit reticulocytes, and vesicular stomatitis virus protein synthesis, but not cellular protein synthesis, in virus-infected cells. In the second approach, Matagens complementary to splice junctions of precursor mRNAs are used to inhibit splicing. For example, a Matagen complementary to the donor splice junction of simian virus 40 (SV40) large T-antigen mRNA inhibits T-antigen synthesis in SV40-infected cells, and a Matagen complementary to the acceptor splice junction of herpes simplex virus (HSV) immediate early pre-mRNA 4 + 5 inhibits HSV replication in virus-infected cells. Two new types of Matagen, one derivatized with the photoactivatable cross-linking group psoralen and the other derivatized with a hydroxyl radical-producing group, EDTA-Fe(II), have been designed to improve the efficacy of Matagen and to overcome some of the problems inherent in physical binding of Matagens to complementary nucleic acids. The Matagen approach provides a new way to design antiviral and chemotherapeutic agents in a rational manner. It combines nucleic acid chemistry and chemotherapy to form a common basis for drug development as well as to provide fundamental knowledge about organisms and humans." @default.
• W17537284 created "2016-06-24" @default.
• W17537284 creator A5062832309 @default.
• W17537284 creator A5088698626 @default.
• W17537284 date "1987-10-01" @default.
• W17537284 modified "2023-10-17" @default.
• W17537284 title "A new approach to chemotherapy based on molecular biology and nucleic acid chemistry: Matagen (masking tape for gene expression)." @default.
• W17537284 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/3329522" @default.
• W17537284 hasPublicationYear "1987" @default.
• W17537284 type Work @default.
• W17537284 sameAs 17537284 @default.
• W17537284 citedByCount "24" @default.
• W17537284 crossrefType "journal-article" @default.
• W17537284 hasAuthorship W17537284A5062832309 @default.
• W17537284 hasAuthorship W17537284A5088698626 @default.
• W17537284 hasConcept C104317684 @default.
• W17537284 hasConcept C105580179 @default.
• W17537284 hasConcept C129312508 @default.
• W17537284 hasConcept C149364088 @default.
• W17537284 hasConcept C150194340 @default.
• W17537284 hasConcept C153911025 @default.
• W17537284 hasConcept C185592680 @default.
• W17537284 hasConcept C24107716 @default.
• W17537284 hasConcept C55493867 @default.
• W17537284 hasConcept C67705224 @default.
• W17537284 hasConcept C86803240 @default.
• W17537284 hasConceptScore W17537284C104317684 @default.
• W17537284 hasConceptScore W17537284C105580179 @default.
• W17537284 hasConceptScore W17537284C129312508 @default.
• W17537284 hasConceptScore W17537284C149364088 @default.
• W17537284 hasConceptScore W17537284C150194340 @default.
• W17537284 hasConceptScore W17537284C153911025 @default.
• W17537284 hasConceptScore W17537284C185592680 @default.
• W17537284 hasConceptScore W17537284C24107716 @default.
• W17537284 hasConceptScore W17537284C55493867 @default.
• W17537284 hasConceptScore W17537284C67705224 @default.
• W17537284 hasConceptScore W17537284C86803240 @default.
• W17537284 hasIssue "2" @default.
• W17537284 hasLocation W175372841 @default.
• W17537284 hasOpenAccess W17537284 @default.
• W17537284 hasPrimaryLocation W175372841 @default.
• W17537284 hasRelatedWork W1492275480 @default.
• W17537284 hasRelatedWork W1989800893 @default.
• W17537284 hasRelatedWork W2029610180 @default.
• W17537284 hasRelatedWork W2039758446 @default.
• W17537284 hasRelatedWork W2084804290 @default.
• W17537284 hasRelatedWork W2139273728 @default.
• W17537284 hasRelatedWork W2164497648 @default.
• W17537284 hasRelatedWork W2515334174 @default.
• W17537284 hasRelatedWork W2950341776 @default.
• W17537284 hasRelatedWork W3179597092 @default.
• W17537284 hasVolume "2" @default.
• W17537284 isParatext "false" @default.
• W17537284 isRetracted "false" @default.
• W17537284 magId "17537284" @default.
• W17537284 workType "article" @default.